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Clinical Infectious Diseases
SUPPLEMENT ARTICLE
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Background. Lack of a gold standard for identifying bacterial and viral etiologies of pneumonia has limited evaluation of
C-reactive protein (CRP) for identifying bacterial pneumonia. We evaluated the sensitivity and specificity of CRP for identifying
bacterial vs respiratory syncytial virus (RSV) pneumonia in the Pneumonia Etiology Research for Child Health (PERCH) multicenter case-control study.
Methods. We measured serum CRP levels in cases with World Health Organization–defined severe or very severe pneumonia
and a subset of community controls. We evaluated the sensitivity and specificity of elevated CRP for “confirmed” bacterial pneumonia (positive blood culture or positive lung aspirate or pleural fluid culture or polymerase chain reaction [PCR]) compared to “RSV
pneumonia” (nasopharyngeal/oropharyngeal or induced sputum PCR-positive without confirmed/suspected bacterial pneumonia).
Receiver operating characteristic (ROC) curves were constructed to assess the performance of elevated CRP in distinguishing these
cases.
Results. Among 601 human immunodeficiency virus (HIV)–negative tested controls, 3% had CRP ≥40 mg/L. Among 119 HIVnegative cases with confirmed bacterial pneumonia, 77% had CRP ≥40 mg/L compared with 17% of 556 RSV pneumonia cases.
The ROC analysis produced an area under the curve of 0.87, indicating very good discrimination; a cut-point of 37.1 mg/L best discriminated confirmed bacterial pneumonia (sensitivity 77%) from RSV pneumonia (specificity 82%). CRP ≥100 mg/L substantially
improved specificity over CRP ≥40 mg/L, though at a loss to sensitivity.
Conclusions. Elevated CRP was positively associated with confirmed bacterial pneumonia and negatively associated with RSV
pneumonia in PERCH. CRP may be useful for distinguishing bacterial from RSV-associated pneumonia, although its role in discriminating against other respiratory viral-associated pneumonia needs further study.
Keywords. C-reactive protein; bacteria; RSV; biomarker; pneumonia.
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C-reactive protein (CRP) is an acute phase plasma protein synthesized by hepatocytes and adipocytes in response to inflammatory cytokines and is an indicator of acute inflammation
[1]. First identified in sera from pneumonia patients in 1930 by
its ability to precipitate the C-polysaccharide of Streptococcus
pneumoniae [2], CRP has since been associated with bacterial infections generally [3] and with noninfectious causes of
inflammation [1, 4]. These associations have led to the use of
CRP for discriminating between bacterial and nonbacterial
pneumonia.
Several studies have found higher CRP levels in bacterial
than viral pneumonia [5–16], whereas others have not [17–19].
Even in those detecting a difference, overlapping CRP distributions indicate imperfect specificity for bacterial pneumonia.
The variation in reported utility of CRP for distinguishing etiologic class in pneumonia likely results from small sample sizes,
lack of specific tests for accurately categorizing bacterial and
viral pneumonia, and differences across studies in case groups,
severity of disease, and comparison groups.
The Pneumonia Etiology Research for Child Health
(PERCH) study provides an opportunity to examine the association between CRP and etiology of pneumonia in a number of
children in several countries [20]. We describe the distribution
of CRP among PERCH cases and a subset of community controls and examine factors associated with elevated CRP among
both groups. We also evaluate the sensitivity and specificity of
elevated CRP for bacterial pneumonia in comparison to pneumonia likely caused by respiratory syncytial virus (RSV), the
most common respiratory virus associated with childhood
pneumonia [21].
METHODS

PERCH evaluated etiologic agents causing severe and very severe
pneumonia among children <5 years of age in 9 sites across 7
countries: Dhaka and Matlab, Bangladesh; Basse, The Gambia;
Kilifi, Kenya; Bamako, Mali; Soweto, South Africa; Nakhon
Phanom and Sa Kaeo, Thailand; and Lusaka, Zambia [20].
Identification and selection of cases and controls have been
described previously [22]. In brief, cases were hospitalized
children aged 1–59 months with World Health Organization
(WHO)–defined severe or very severe pneumonia [23].
Controls were randomly selected children from the community without severe or very severe pneumonia and frequency
matched by age and month of enrollment to cases. In South
Africa and Zambia where the human immunodeficiency virus
(HIV) prevalence was high, controls were also frequency
matched on HIV.
Blood, nasopharyngeal/oropharyngeal (NP/OP) swabs, and
induced sputum were collected from PERCH cases at enrollment. Pleural fluid was collected from cases when clinically
indicated. Lung aspirates were collected among a subset of cases
meeting eligibility criteria [24] at the Bangladesh, The Gambia,

Mali, and South Africa sites. Blood and NP/OP swabs were collected from PERCH controls.
Pathogen-specific testing methods by body fluid have also
been described elsewhere [25]. In brief, NP/OP, induced sputum, lung aspirates, and pleural fluid were tested by quantitative
real-time polymerase chain reaction (PCR) using the Fast Track
Diagnostics Respiratory Pathogens 33 test (FTD Resp-33) (Fasttrack Diagnostics, Sliema, Malta) for select viruses and bacteria.
Lung aspirates and pleural fluid were also tested by Gram stain
and bacterial culture. Whole blood among cases and controls
was tested by real-time PCR for pneumococcus only; blood cultures were performed on cases using standardized automated
systems.
CRP levels were measured in all PERCH cases from whom
serum specimens were collected. To assess specificity for bacterial pneumonia, we evaluated elevated CRP among those most
likely to have viral pneumonia, cases with RSV pneumonia
(defined below). We also assessed CRP specificity by testing sera
from a subset of community controls at each site, children who
by definition did not have severe or very severe pneumonia,
whether bacterial or otherwise. The subset of controls tested
for CRP was enriched with children potentially more likely to
have elevated CRP. This was achieved by oversampling from
those who were positive for pneumococcus by whole-blood
PCR, had a respiratory tract illness (defined below), had a total
NP/OP PCR pathogen load (across all pathogens tested for) in
the top 25% of controls at each site, or who were HIV-infected.
Serum samples from South Africa were tested locally using
CRP Gen3 Immunoturbidometric assay (Roche Diagnostics,
Milan, Italy). Serum specimens from the other sites were tested
for CRP at the PERCH reference laboratory in Christchurch,
New Zealand, using CRP VARIO Immunoturbidometric assay
(Roche Diagnostic, Milan, Italy).
Definitions

Respiratory tract illness (RTI) in controls was defined as having
cough or runny nose. RTI was also defined as having (1) at least
1 of ear discharge, wheezing, or difficulty breathing and (2)
either a measured temperature of ≥38.0°C within the previous
48 hours or a history of sore throat. Chest radiograph positive
(CXR+) was defined as chest radiograph performed up to 72
hours after presentation at study sites with evidence of alveolar consolidation (CXR-AC) or any other infiltrate (CXR-OI)
by the WHO interpretation criteria [26, 27]. Confirmed bacterial pneumonia was defined as any noncontaminant bacterial pathogen detected by culture of blood; by PCR or culture
of lung aspirate; or by PCR, culture, or pneumococcal antigen
detection (BinaxNOW) of pleural fluid. Confirmed viral pneumonia was defined as any virus detected from lung aspirate or
pleural fluid by PCR. Suspected bacterial pneumonia cases were
cases who met all the following criteria: RSV-negative by NP/
OP and induced sputum PCR; absence of confirmed bacterial
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and confirmed viral pneumonia; and NP/OP PCR Streptococcus
pneumoniae (Spn) density >106.9 copies/mL or whole-blood
PCR Spn density >102.2 copies/mL or NP/OP PCR Haemophilus
influenzae (Hinf) density >105.9 copies/mL (these PERCH
thresholds that distinguished bacterial pneumonia cases due
to Spn and Hinf from controls are described elsewhere in this
supplement [28–30]). Respiratory syncytial virus positivity
(RSV+) was defined as detection of RSV by PCR from NP/
OP or induced sputum. For the purpose of this analysis, RSV
pneumonia was defined as RSV+ cases without any of the following: confirmed bacterial pneumonia; high-density Spn (NP/
OP PCR Spn density >106.9 copies/mL or whole-blood PCR Spn
density >102.2 copies/mL); and high-density Hinf (NP/OP PCR
Hinf density >105.9 copies/mL).

Spn or Hinf. We also compared joint positivity among cases to
the subset of controls that were selected for CRP testing.
Statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, North Carolina). All P values provided were obtained from logistic regression analyses adjusting
for age and site unless otherwise noted.
Ethical Considerations

The PERCH study protocol was approved by the institutional
review board or ethical review committee at each of the study
site institutions and at the Johns Hopkins Bloomberg School of
Public Health. Parents or guardians of all participants provided
written informed consent.
RESULTS

Statistical Analysis

Analyses were restricted to HIV-negative cases and controls
unless otherwise noted. We evaluated the association of demographic and clinical factors with CRP ≥40 mg/L among CXR+
cases and among controls using logistic regression to adjust for
age and site, with CRP ≥40 mg/L as the outcome. We also compared these characteristics among controls tested vs not tested
for CRP. Because the subset of controls selected for CRP testing
intentionally targeted elevated CRP, the proportion with elevated CRP is not representative of the prevalence in children in
the community; therefore, we did not compare the distribution
of CRP results between cases and controls.
Because there is no gold standard for determining viral etiology and because RSV was the only virus strongly associated
with case-control status (odds ratio >7.0 at every site), we limited analyses of viral pneumonia to just RSV-associated pneumonia cases. We calculated the proportion of children with
elevated CRP among subgroups with increasing likelihood of
bacterial pneumonia (and decreasing likelihood of RSV pneumonia): CXR-normal cases, CXR-OI cases (without CXR-AC),
and CXR-AC cases (with or without CXR-OI). We assessed
the performance of CRP in distinguishing confirmed bacterial pneumonia from RSV pneumonia using receiver operating
characteristic (ROC) analysis with the area under the curve
(AUC) statistic [31]; the Youden index was used to determine
the best differentiating cut-point [32]. To guard against bias in
the estimates of sensitivity due to small numbers of confirmed
cases, the Youden index was calculated using leave-one-out
cross-validation where applicable [33].
Using Spn as an example, we explored whether additionally
requiring elevated CRP could improve the specificity of pathogen-specific measures of high pathogen load (NP/OP Spn PCR
density >106.9 copies/mL; whole-blood Spn PCR density >102.2
copies/mL) to identify Spn pneumonia. We compared the joint
positivity of elevated CRP and high pathogen load among cases
with confirmed Spn pneumonia to RSV+ cases that did not have
a confirmed bacterial infection but may have had high-density
S380 • CID 2017:64 (Suppl 3) • Higdon et al

Among 3981 HIV-negative cases, 3357 (84%) had CRP
measured. CRP ≥40 mg/L was observed in 28% of all HIVnegative cases and was more frequent among CXR+ cases
(35%) than among CXR-normal cases (20%, P < .001; Table 1).
CRP ≥100 mg/L was found in 11% of all HIV-negative cases and
again was more common among CXR+ cases (15%) than CXRnormal cases (6%, P < .001; data not shown).
Factors Associated With Elevated CRP

CRP ≥40 mg/L was associated with HIV status: 45% of 159
HIV-positive CXR+ cases with available CRP results had
CRP ≥40 mg/L compared with 35% of 1508 HIV-negative
CXR+ cases (P = .009). Among HIV-negative CXR+ cases,
the proportion with CRP ≥40 mg/L was higher at the African
sites (range, 31% in South Africa to 49% in The Gambia)
than at Asian sites (13% in Bangladesh and 24% in Thailand).
Additionally, among HIV-negative CXR+ cases, CRP ≥40 mg/L
was more common among older children and those with very
severe pneumonia, fever, or absence of wheeze (all P ≤ .001,
adjusted for site and age; Supplementary Table 1). Among
HIV-positive CXR+ cases, CRP ≥40 mg/L was similarly more
common among older children and those with very severe
pneumonia (P = .01 and P = .03, respectively, adjusted for site
and age; data not shown).
CRP Results Among Targeted Community Controls

By design, the 601 HIV-negative controls tested for CRP were
more likely to have RTI (43%) and be PCR-positive for pneumococcus in whole blood (36%) than controls not tested (21% and
1%, respectively); 69% of tested controls met at least 1 of these
conditions compared with 23% of controls not tested for CRP
(Supplementary Table 2). Of tested controls, 12% (95% confidence interval [CI], 9%–15%) had CRP ≥10 mg/L and 3% (95%
CI, 2%–4%) had CRP ≥40 mg/L. Of several factors examined,
only pneumococcal PCR positivity in whole blood was associated with CRP ≥40 mg/L after adjusting for site and age. The
proportion of tested HIV-negative controls with CRP ≥40 mg/L

Table 1. Distribution of C-Reactive Protein Among Severe and Very Severe Pneumonia Cases—Pneumonia Etiology Research for Child Health (PERCH)
Study
CXR Status
CRP Level, mg/L
HIV-negative

All Cases

CXR-ACa

CXR-OIb

All CXR+c

CXR-Normal
(n = 1339)

(n = 3357)

(n = 729)

(n = 769)

(n = 1508)

<10

1422 (42.4)

204 (27.6)

326 (42.4)

530 (35.2)

640 (47.8)

10 to <40

1010 (30.1)

199 (26.9)

253 (32.9)

452 (30.0)

435 (32.5)

925 (27.6)

336 (45.5)

190 (24.7)

526 (34.9)

264 (19.7)

(n = 240)

(n = 120)

(n = 39)

(n = 159)

(n = 24)

<10

83 (34.6)

33 (27.5)

13 (33.3)

46 (28.9)

10 (41.7)

10 to <40

59 (24.6)

27 (22.5)

14 (35.9)

41 (25.8)

4 (16.7)

≥40

98 (40.8)

60 (50.0)

12 (30.8)

72 (45.3)

10 (41.7)

≥40
HIV-positive

P Valued, All CXR+ vs
CXR-Normal
<.001

.98

Data are presented as No. (%) unless otherwise indicated.
Abbreviations: AC, alveolar consolidation; CRP, C-reactive protein; CXR, chest radiograph; HIV, human immunodeficiency virus; OI, other infiltrate.
a

CXR-AC: radiographic evidence of alveolar consolidation with or without any other infiltrate.

b

CXR-OI: radiographic evidence of any other infiltrate without evidence of alveolar consolidation.

c

All CXR+: radiographic evidence of alveolar consolidation, any other infiltrate, or both (includes both CXR-AC and CXR-OI cases).

d

P value comparing CRP <40 vs CRP ≥40 mg/L, adjusted for age and site.

varied by site, ranging from 0% in Zambia and South Africa to 7%
in The Gambia. CRP ≥40 mg/L was also more frequent among
controls who had at least 1 of RTI, NP/OP Spn density >106.9
copies/mL, or whole-blood PCR positivity for pneumococcus
(3% vs 1% among controls with none of these characteristics).
Of 221 HIV-positive controls enrolled at the South African
and Zambian sites, 81 (37%) were tested for CRP. CRP ≥40 mg/L
was more common among the HIV-positive (11%; 95% CI,
4%–18%) than the HIV-negative (3%) controls selected for testing across all PERCH sites as was CRP ≥10 mg/L (30% vs 12%,
data not shown). No factors were found to be associated with
CRP ≥40 mg/L among the HIV-positive controls, but sample
size was small (data not shown).
Association of Elevated CRP With Bacterial Versus RSV Pneumonia

Of 842 HIV-negative RSV+ cases, 286 (34%) were excluded
from the RSV pneumonia case group because they had a confirmed bacterial infection (n = 9), high-density Spn in the NP/
OP (n = 111) or whole blood (n = 22), or high-density Hinf in
the NP/OP (n = 199).
Among 119 HIV-negative cases with confirmed bacterial
pneumonia, 77% had CRP ≥40 mg/L compared with 17% of
556 cases with RSV pneumonia (P < .001). Of the 286 excluded
RSV+ cases, 85 (30%) had CRP ≥40 mg/L.
Among HIV-positive cases, differences were less extreme but
trends were similar, though small numbers limit interpretation: 69% of 26 cases with confirmed bacterial pneumonia had
CRP ≥40 mg/L compared with 45% of 11 cases with RSV pneumonia (data not shown; P = .41).
An abnormal chest radiograph was associated with
CRP ≥40 mg/L among HIV-negative cases with RSV pneumonia (24% of CXR+ vs 12% of CXR-normal cases, P < .001) but
not cases with confirmed bacterial pneumonia (77% vs 75%;
Supplementary Table 4). However, among CXR+ cases in both

groups, the percentage with elevated CRP was higher among cases
with CXR-AC than cases with CXR-OI: 85% vs 50% (P = .004)
among confirmed bacterial pneumonia cases and 31% vs 18%
(P = .01) among RSV pneumonia cases (Figure 1, Supplementary
Table 4). High CRP (≥100 mg/L) was very common among the
CXR-AC cases with confirmed bacterial pneumonia (71%) and
uncommon (4%) among RSV pneumonia cases (Figure 1).
Among the confirmed bacterial pneumonia cases, those
confirmed for either Spn or Hinf had higher CRP (84%
CRP ≥40 mg/L and 74% CRP ≥100 mg/L) than cases confirmed for other bacteria (69% CRP ≥40 mg/L, P = .18 and 45%
CRP ≥100 mg/L, P = .02; Supplementary Table 5).
ROC analyses showed that CRP had good accuracy in distinguishing cases with confirmed bacterial infection from RSV
pneumonia cases (AUC = 0.87, Figure 2); the CRP cut-point
that produced optimal differentiation was 37.1 mg/L with a corresponding sensitivity of 77% (95% CI, 69%–84%) and specificity of 82% (95% CI, 78%–85%). When trying to distinguish
confirmed Spn cases from RSV pneumonia, the AUC increased
to 0.91; the optimal cut-point was 88.9 mg/L, resulting in a
sensitivity and specificity of 79% (95% CI, 64%–89%) and 95%
(95% CI, 93%–97%), respectively. The AUC for distinguishing
confirmed Hinf cases from RSV pneumonia cases was also 0.91;
the optimal cut-point of 52.3 mg/L produced a sensitivity and
specificity of 80% (95% CI, 58%–92%) and 86% (95% CI, 83%–
89%), respectively.
Value of CRP to Increase Specificity of Other Etiology Laboratory
Measurements

We assessed how combining elevated CRP with Spn density
measures improved the specificity over Spn density measures
alone in differentiating confirmed pneumococcal cases from:
(1) RSV+ cases without confirmed bacterial coinfection and (2)
community controls tested for CRP. The percentage of RSV+
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Figure 1. Percentage of cases with elevated (≥40 mg/L) and high (≥100 mg/L) C-reactive protein by (approximate) increasing likelihood of bacterial etiology. Confirmed bacterial pneumonia: bacterial pathogen identified by blood culture, by culture or polymerase chain reaction (PCR) of lung aspirate or pleural fluid, or Streptococcus pneumoniae
identified by BinaxNOW assay of pleural fluid. Respiratory syncytial virus (RSV) pneumonia: RSV identified by nasopharyngeal/oropharyngeal (NP/OP) PCR or induced sputum
PCR excluding (1) confirmed bacterial cases and (2) cases with whole-blood pneumococcal density >102.2 copies/mL, or NP/OP pneumococcal PCR density >106.9 copies/mL,
or Haemophilus influenzae NP/OP PCR density >105.9 copies/mL. Vertical bars: 95% confidence intervals. Abbreviations: CXR+, cases with radiographic evidence of alveolar
consolidation, any other infiltrate, or both; CXR-AC, cases with radiographic evidence of alveolar consolidation (with or without any other infiltrate); CXR-OI, cases with
radiographic evidence of any other infiltrate only.

cases and tested community controls with both CRP ≥40 mg/L
and high density Spn in the NP/OP was 4% and 1%, respectively,
compared with 13% and 12%, respectively, with high NP/OP
density alone. This gain in specificity came without substantial
loss in sensitivity, declining from 58% of confirmed Spn cases
with high NP/OP density to 47% who also had CRP ≥40 mg/L
(Table 2). Less than 1% of RSV+ cases and 0% of tested controls
had high Spn NP/OP density and CRP ≥100 mg/L compared
with 42% of confirmed Spn cases.
Because the optimal whole-blood Spn PCR density cutpoint identified in ROC analyses had high specificity as a single measure (only 2% of RSV+ cases had high density Spn in
whole blood), also requiring CRP ≥40 mg/L increased specificity only minimally (0.4% positive for both measurements).
However, the gain in specificity was larger when compared
to the tested community controls: 20% had high-density Spn in whole blood compared with 0.8% who also had
CRP ≥40 mg/L.
DISCUSSION

This large study of hospitalized severe and very severe pneumonia from 7 countries in Africa and Asia showed that elevated CRP was positively associated with confirmed bacterial
pneumonia and negatively associated with RSV pneumonia as defined for this analysis. The percentage of cases with
CRP ≥40 mg/L varied by site, age, HIV status, CXR findings,
severity, presence of fever, and wheeze. Among community
controls targeted for CRP testing because of suspected potential for elevated CRP, the proportion with CRP ≥40 mg/L was
S382 • CID 2017:64 (Suppl 3) • Higdon et al

low (3% among HIV-negative controls and 11% among HIVpositive controls) but specificity was not 100%.
We conducted this analysis to see if CRP could be a useful
diagnostic to distinguish bacterial from viral pneumonia. But
because there is no gold standard for diagnosing viral pneumonia, we limited our analysis of viruses solely to RSV since
RSV was the only viral pathogen assessed that was both rarely
observed in the NP/OP of controls and strongly associated with
case status. That evidence suggested RSV was causally associated with the pneumonia episode in a large fraction of the RSV+
cases. However, severe and very severe pneumonia associated
with RSV may not be representative of pneumonias associated
with other viruses as viruses might differ in their propensity
to cause bacterial super- or coinfections. In our analyses, we
excluded RSV+ cases who may have had bacterial coinfection,
an important and potentially substantial subgroup of cases with
bacterial–viral coinfection. Other studies of children with respiratory infections that have observed increased CRP levels
among cases with certain viruses detected have a similar problem of inability to rule out concurrent bacterial infections and
inability to confirm viral etiology because of lack of gold standard tests [34–37]. Because our analyses assessed a case group
that likely had true RSV pneumonia, we concluded that elevated
CRP levels were more common in bacterial than RSV pneumonia. However, our conclusions cannot extend to other viruses as
the negative association found in PERCH between RSV pneumonia and elevated CRP may not be true of all viruses.
Another challenge in interpreting elevated CRP was that the
proportion with CRP ≥40 mg/L varied by bacterial pathogen;

Figure 2. A–D, Receiver operating characteristic curves and area under the curve (AUC) for C-reactive protein in differentiating confirmed bacterial pneumonia from probable respiratory syncytial virus (RSV) pneumonia among human immunodeficiency virus–negative Pneumonia Etiology Research for Child Health (PERCH) cases. aCases with
any noncontaminant bacteria identified by blood culture, by culture or polymerase chain reaction (PCR) of lung aspirate or pleural fluid, or with Streptococcus pneumoniae
identified by BinaxNOW assay of pleural fluid. bRSV identified by nasopharyngeal/oropharyngeal (NP/OP) PCR or induced sputum PCR, excluding high-density bacterial cases
(Streptococcus pneumoniae cases with whole-blood PCR density >102.2 copies/mL, or NP/OP density >106.9 copies/mL, and Haemophilus influenzae cases with NP/OP density
>105.9 copies/mL) and confirmed bacterial cases. cCases with S. pneumoniae identified by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR or
BinaxNOW. dCases with H. influenzae identified by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR. eCases with a bacterial pathogen identified
by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR (excluding confirmed S. pneumoniae and H. influenzae cases).

CRP was higher among cases confirmed for Spn and Hinf than
cases confirmed for other bacteria. Although sample size was
limited and the difference was not statistically significant, this
may suggest that the CRP response could vary by bacterial pathogen. However, it is also possible that this indicates imperfect
specificity of determining bacterial pneumonia, as the majority of the “confirmed” bacterial cases were diagnosed based on
detection of bacteria in the blood and may not represent the
infection in the lung.
If the distribution of CRP differs by bacteria, then the relative
distribution of bacterial etiologies among the cases will affect

the calculation of CRP cut-points for distinguishing bacterial
from RSV pneumonia cases. Because the CRP cut-points calculated in this analysis were selected to maximize the sum of
sensitivity and specificity for our data, they may not be representative of other settings and are presented for descriptive purposes only. However, they may have utility in determining or
corroborating etiology results within the PERCH study.
In clinical practice, a test that has both high specificity and
sensitivity to identify bacterial infection would be helpful to
identify those children who would benefit from antibiotic therapy. The WHO definition of severe and very severe pneumonia
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Table 2. C-Reactive Protein Combined With Pneumococcal Nasopharyngeal/Oropharyngeal and Whole-Blood Polymerase Chain Reaction Density
Measures for Distinguishing Confirmed Pneumococcal Pneumonia From Respiratory Syncytial Virus–Positive Cases, Controls Targeted for CRP Testing,
and Confirmed Other Bacterial Cases

Confirmed Spn
Casesa

Density Measure
NP/OP PCR Spn density

RSV+
Casesb

Controls
Targeted for
CRP Testingc

Confirmed NonSpn Bacterial
Casesd

(n = 36)

(n = 858)

(n = 597)

(n = 79)

21 (58.3)

109 (12.7)

73 (12.2)

20 (25.3)

+ CRP ≥40 mg/L

17 (47.2)

33 (3.9)

3 (0.5)

17 (21.5)

+ CRP ≥100 mg/L

15 (41.7)

8 (0.9)

0 (0.0)

14 (17.7)

NP/OP PCR density > 106.9 copies/mLe alone

Whole-blood PCR Spn density

(n = 35)

(n = 847)

(n = 597)

(n = 78)

Density >102.2 copies/mLe alone

18 (51.4)

19 (2.2)

119 (19.9)

4 (5.1)

+ CRP ≥40 mg/L

17 (48.6)

3 (0.4)

5 (0.8)

3 (3.9)

+ CRP ≥100 mg/L

16 (45.7)

1 (0.1)

1 (0.2)

1 (1.3)

(n = 34)

(n = 835)

(n = 593)

(n = 77)

NP/OP PCR Spn density or whole-blood PCR Spn density
(NP/OP density >106.9 copies/mL or whole-blood density >102.2 copies/mL)e alone

27 (79.4)

126 (15.1)

179 (30.2)

23 (29.9)

+ CRP ≥40 mg/L

23 (67.7)

35 (4.2)

8 (1.4)

19 (24.7)

+ CRP ≥100 mg/L

21 (61.8)

9 (1.1)

1 (0.2)

15 (19.5)

(n = 37)

(n = 870)

(n = 601)

(n = 80)

(NP/OP density >106.9 copies/mL and whole-blood density >102.2 copies/mL)e alone

12 (32.4)

2 (0.2)

13 (2.2)

1 (1.3)

+ CRP ≥40 mg/L

11 (29.7)

1 (0.1)

0 (0.0)

1 (1.3)

+ CRP ≥100 mg/L

10 (27.0)

0 (0.0)

0 (0.0)

0 (0.0)

NP/OP PCR Spn density and whole-blood PCR Spn density

Data are presented as No. (%) positive unless otherwise indicated.
Abbreviations: CRP, C-reactive protein; NP/OP, nasopharyngeal/oropharyngeal; PCR, polymerase chain reaction; RSV, respiratory syncytial virus; Spn, Streptococcus pneumoniae.
a

Spn detected by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR or BinaxNOW assay.

b

RSV detected by NP/OP PCR or induced sputum PCR, excluding confirmed Spn cases and confirmed other bacterial cases.

c

Controls selected for CRP testing were children more likely to have elevated CRP levels (a higher proportion had respiratory symptoms, were whole-blood Spn PCR positive, and/or had
high total NP/OP pathogen load compared to controls not tested).
d

Any non-Spn bacterial pathogen detected by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR.

e

Cut-points obtained from receiver operating characteristic analyses that maximized Youden index in distinguishing confirmed Spn cases from community controls.

was designed to be very sensitive (at the expense of specificity), to identify as many cases of bacterial etiology as possible
in resource-poor settings for treatment with antibiotics. As a
result, many cases meeting the definition do not have a bacterial infection. While CRP ≥40 mg/L may be a fairly specific
marker to rule out most RSV pneumonias (83% of RSV pneumonia cases had CRP <40 mg/L), it had inadequate sensitivity
as 23% of cases with confirmed bacterial severe or very severe
pneumonia also had CRP <40 mg/L. Our findings confirm the
current consensus in the literature, which is that while CRP is
elevated in bacterial pneumonia, CRP alone is not sufficient for
diagnosing bacterial pneumonia.
In addition to being able to distinguish between cases with
bacterial vs RSV pneumonia, the informative value of CRP in
etiology studies includes its ability to distinguish between bacterial pneumonia cases and controls without pneumonia. CRP
levels among controls can be used to determine a reasonable
minimal threshold to serve as a reliable biomarker for bacterial pneumonia. Reports of CRP levels in healthy children
1–59 months in the published literature are few and often have
limited sample sizes (≤100 controls) or include older children
[38–42]; thus, this analysis serves to anchor any conclusions on
the practical application of the utility of CRP levels as a diagnostic tool for bacterial pneumonia in this age group. Though,
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because the controls selected for testing in our study deliberately targeted those thought to have a higher likelihood of
elevated CRP, an analysis comparing controls to cases would
have been biased by underestimating specificity for bacterial pneumonia. Even with the targeted sampling of controls
for CRP testing, 88% of tested HIV-negative controls had
CRP levels <10 mg/L. Nevertheless, the 3% found with CRP
≥40 mg/L demonstrates the lack of perfect specificity of this
marker for identifying bacterial pneumonia. Of the 168 tested
HIV-negative controls who did not have an RTI nor high-density Spn in NP/OP nor Spn detected in whole blood by PCR,
1 (0.6%) still had CRP ≥40 mg/L. This child, who had a CRP
level of 81.3 mg/L, was 5 months of age from the Mali site with
no signs of illness or malnutrition and no apparent factors for
elevated CRP.
Combining CRP with pathogen-specific measurements
increased their specificity for distinguishing bacterial from RSV
etiology as we demonstrated for Spn without substantial loss to
sensitivity. But CRP does not distinguish between bacterial etiologies even though CRP was somewhat higher among cases
confirmed for Spn or Hinf than among cases confirmed for
other bacteria.
For pneumonia, identifying cases with a confirmed etiology
is possible in only a small subset because lung aspirates and

pleural fluid specimens are obtained from very few cases and
blood culture has low sensitivity, especially when blood culture
volume is low or antibiotics are administered prior to specimen
collection. Therefore, because few bacterial pneumonia cases
have a confirmed etiology, the RSV pneumonia cases in our
analysis could have included children with undetected bacterial coinfection. Misclassifications of this type would result in
overestimating the proportion of RSV pneumonia cases with
elevated CRP, and thus the specificity of CRP for detecting bacterial compared to viral pneumonia may be higher.
Our analyses showed that elevated CRP was positively associated with confirmed bacterial pneumonia, especially Spn and
Hinf, and negatively associated with RSV pneumonia. However,
the variation in the distribution of CRP among study sites for
both cases and controls and by clinical factors such as HIV suggests that optimal cut-points for diagnostic utility may vary by
setting or geographic location. While CRP had imperfect specificity for distinguishing bacterial from RSV pneumonia and
therefore limited use as a diagnostic tool, the clear association
of elevated CRP with bacterial pneumonia makes it potentially
useful in epidemiologic studies on bacterial pneumonia, as
cases with low CRP could be assumed to have lower probability
of bacterial etiology than cases with high CRP. The role of CRP
in discriminating between bacterial pneumonia and viral pneumonias other than RSV warrants further study.
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